6 research outputs found
Single-use equipment for handling and manufacturing of highly potent APIs
The industry embraced single-use technology early on after first off the shelf solutions were brought to the market. Initially focused on cell cultures and cell culture products, the use of single-use production solutions expanded over the last decade into other selected technology areas.
The bioconjugates custom manufacturing offering of Lonza has about a 10 years history. While glass and stainless steel based manufacturing equipment dominated in the beginning, the face of bioconjugates manufacture changed in the meantime quite dramatically. Only 7 years after launch of the new market offering, we achieved first successful end-to-end production out of single-use equipment.
Handling of bioconjugates and especially the toxin payload poses a major challenge. The concept of product (patient) safety, a focus in biopharmaceuticals production, is to be amended by the containment and safe working environment aspect. Advantages, caveats and remaining challenges will be discussed
Industrial scale suspension culture of living cells
The submersed cultivation of organisms in sterile containments or fermenters has become the standard manufacturing procedure, and will remain the gold standard for some time to come. This book thus addresses submersed cell culture and fermentation and its importance for the manufacturing industry. It goes beyond expression systems and integrally investigates all those factors relevant for manufacturing using suspension cultures. In so doing, the contributions cover all industrial cultivation methods in a comprehensive and comparative manner, with most of the authors coming from the industry itself. Depending on the maturity of the technology, the chapters address in turn the expression system, basic process design, key factors affecting process economics, plant and bioreactor design, and regulatory aspects
Industrial scale suspension culture of living cells
Weinheim, Germanyxxix, 612 p.: bibl. ref., index; 25 c
BPMSS – Lonza's Biopharmaceutical Small Scale Plant Started cGMP Manufacturing in September 2004
In September 2004 Lonza (Visp, Switzerland) started operations in a new state of the art facility for cGMP manufacture of injectable grade microbially derived biopharmaceuticals. Both intracellular and secreted products can be processed in the new production line, which delivers bulk
drug substances. cGMP conformity, including clean room classification, was cross-checked during the design phase with the Swiss regulatory authorities. The layout of the highly automated multi-product line is based on a high performance 1000 l bioreactor suitable for high cell density fermentation.
Besides standard chromatography and ultrafiltration, the ex-proof design in upstream and downstream areas allows for solvent feeds in fermentation and for implementation of HPLC purification steps in protein and peptide purification